Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -5% Improvement Relative Risk Discharge 20% c19hcq.org Sbidian et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 4,642 patients in France Higher discharge with HCQ (p=0.002) Sbidian et al., medRxiv, doi:10.1101/2020.06.16.20132597 Favors HCQ Favors control
Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France
Sbidian et al., medRxiv, doi:10.1101/2020.06.16.20132597 (Preprint)
Sbidian et al., Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients.., medRxiv, doi:10.1101/2020.06.16.20132597 (Preprint)
Jun 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective of 4,642 hospitalized patients in France showing significantly faster discharge with HCQ and HCQ+AZ. No significant effect is seen on 28-day mortality, however many more control patients are still in hospital at 28 days. Other studies show faster resolution for HCQ, suggesting there will be a significant improvement when extending past 28 days. Hopefully authors will extend the analysis. Note that the median age is higher in the group not treated with HCQ or AZ.
For other issues with the adjustments see [medrxiv.org]. Also see the analysis here [twitter.com]. This study is excluded in the after exclusion results of meta analysis: significant issues found with adjustments.
risk of death, 5.0% higher, RR 1.05, p = 0.74, treatment 111 of 623 (17.8%), control 830 of 3,792 (21.9%), adjusted per study, whole population HCQ AIPTW adjusted.
risk of no hospital discharge, 20.0% lower, RR 0.80, p = 0.002, treatment 623, control 3,792, adjusted per study, inverted to make RR<1 favor treatment, whole population HCQ AIPTW adjusted.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sbidian et al., 19 Jun 2020, retrospective, database analysis, France, preprint, 21 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.06.16.20132597; this version posted June 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France Emilie Sbidian,1,2,3* Julie Josse,4,5* Guillaume Lemaitre,6 Imke Meyer,7 Mélodie Bernaux,8 Alexandre Gramfort,4 Nathanaël Lapidus,9 Nicolas Paris,10 Antoine Neuraz,11,12 Ivan Lerner,11,12 Nicolas Garcelon,11,13 Bastien Rance,11,14 Olivier Grisel,4 Thomas Moreau,4 Ali Bellamine,10 Pierre Wolkenstein,2 Gaël Varoquaux,4 Eric Caumes,15,16 Marc Lavielle,4,5 Armand Mekontso Dessap,17 Etienne Audureau18,19 On behalf of AP-HP/Universities/Inserm COVID-19 research collaboration ; AP-HP Covid CDR Initiative and ‘Entrepôt de Données de Santé’ AP-HP consortium Author Affiliations : 1- University Paris Est Creteil, Reserach unit EpiDermE, Creteil, France 2- AP-HP, Henri-Mondor hospital, Department of Dermatology, Creteil, France 3- INSERM, Centre d'Investigation Clinique 1430, Créteil, France 4- Department of Statistics INRIA, Saclay Paris Sud University, France; 5- Ecole Polytechnique, Palaiseau, France 6- Parietal, Inria Saclay, Palaiseau, France 7- EHESS (Ecole des Hautes études en sciences sociales) 8- Strategy and transformation department, APHP Greater Paris University Hospital 9- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique IPLESP, AP-HP. Sorbonne Université, Public Health Department, SaintAntoine Hospital, Paris, France. 10- WIND Department APHP Greater Paris University Hospital 11- INSERM, UMRS 1138, Cordeliers research center, Sorbonne Université, Paris, France 12- Département d’informatique médicale, Hôpital Necker-Enfants Malades, Assistance Publique - Hôpitaux de Paris (AP-HP), F-75015 Paris, France 13- Institut Imagine, Université Paris Descartes - Université de Paris, F-75015 Paris, France 14- Département d’informatique médicale, Hôpital Européen Georges Pompidou, Assistance Publique - Hôpitaux de Paris (AP-HP), F-75015 Paris, France 15- APHP, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Infectious Diseases department, Paris, France. 16- Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pierre-Louis d'Epidémiologie et de Santé Publique, Paris, France 17- Medical Intensive Care Unit, Henri Mondor Hospital, Créteil, France. 18- Inserm U955, Université Paris Est Créteil (UPEC), Institut Mondor de Recherche Biomédicale (IMRB), équipe CEpiA (Clinical Epidemiology and Ageing), Créteil, France 19- AP-HP, Henri-Mondor hospital, Department of Public Health, Clinical Research Unit, Creteil, France *equally contributed NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2020.06.16.20132597; this version posted June 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Corresponding author: E..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit